Alkermes plc. reported second-quarter 2026 results with revenue of $496M, up 26.9% year over year, while net income fell to $0.5M and diluted EPS was $0 for the quarter.
Financial Highlights
- Revenue was $496.0M for Q2 2026, compared with $390.7M in the year‑ago quarter; YoY change 26.9%.
- Net income was $0.5M for Q2 2026, compared with $87.1M in the year‑ago quarter.
- Diluted earnings per share was $0.00 for Q2 2026, versus $0.52 in the year‑ago quarter.
Business Highlights
- Revenue growth was driven by product sales expansion, including the addition of LUMRYZ and higher LYBALVI volumes, boosting net sales across key brands.
- Changes in channel mix and gross-to-net dynamics affected deductions: Medicaid rebate favorability decreased as a percentage and inclusion of LUMRYZ altered the gross-to-net mix.
- Commercial momentum continued with the LUMRYZ launch and an 18–23% increase in LYBALVI unit sales; ARISTADA volumes rose modestly.
- R&D progress included advancing alixorexton into Phase 3 (Brilliance Studies) and positive topline results from the LUMRYZ REVITALYZ Phase 3 trial.
- Operationally, Alkermes completed the Avadel acquisition, integrated the LUMRYZ commercial organization, and recognized related inventory step-up and operating impacts.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.